European Heart Journal Advance Access originally published online on July 10, 2006
European Heart Journal 2006 27(18):2196-2200; doi:10.1093/eurheartj/ehl137
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes
1 Institute of Sports Medicine and Science, Italian National Olympic Committee, Via dei Campi Sportivi, 46, 00197 Rome, Italy
2 Department of Cardiology, University of Padua, Padua, Italy
3 The Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA
Received 3 February 2006; revised 24 May 2006; accepted 15 June 2006; online publish-ahead-of-print 10 July 2006.
* Corresponding author. Tel: +39 06 3685 9127; fax: +39 06 3685 9256. E-mail address: ant.pelliccia{at}libero.it
See page 2152 for the editorial comment on this article (doi:10.1093/eurheartj/ehl171)
Aims Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden death in young athletes, and substantial interest persists in strategies for timely identification. We assessed the diagnostic efficacy of Italian pre-participation screening programme with 12-lead ECG (in addition to history and physical examination) for identification of HCM.
Methods and results Four thousand four hundred and fifty members of the Italian national teams, initially judged eligible for competition as a result of systematic pre-participation screening across Italy, subsequently underwent clinical and echocardiographic examination at the Institute of Sports Medicine and Science (Rome) to assess the presence of previously undetected HCM. None of the 4450 athletes showed clinical evidence of HCM. Other cardiac abnormalities were detected in only 12 athletes, including myocarditis (n=4), mitral valve prolapse (n=3), Marfan's syndrome (n=2), aortic regurgitation with bicuspid valve (n=2), and arrhythmogenic right ventricular cardiomyopathy (n=1). In addition, echocardiography identified four athletes with borderline left ventricular wall thickness (i.e. 13 mm) in the grey zone of overlap between HCM and athlete's heart. In two of these athletes, subsequent genetic analysis or clinical changes over an average 8-year follow-up resulted, respectively, in a definitive or possible diagnosis of HCM.
Conclusion The Italian national pre-participation screening programme including 12-lead ECG appears to be efficient in identifying young athletes with HCM, leading to their timely disqualification from competitive sports. These data also suggest that routine echocardiography is not an obligatory component of broad-based screening programmes designed to identify young athletes with HCM.
Key Words: Athletes Hypertrophic Cardiomyopathy Pre-participation screening 12-lead ECG Echocardiography
![]()
CiteULike
Connotea
Del.icio.us What's this?
Related articles in EHJ:
- Sudden cardiac death due to hypertrophic cardiomyopathy can be reduced by pre-participation cardiovascular screening in young athletes
- Nicole M. Panhuyzen-Goedkoop and Freek W.A. Verheugt
EHJ 2006 27: 2152-2153.[Extract] [FREE Full Text]
This article has been cited by other articles:
![]() |
D. Corrado, C. Basso, M. Schiavon, A. Pelliccia, and G. Thiene Pre-Participation Screening of Young Competitive Athletes for Prevention of Sudden Cardiac Death J. Am. Coll. Cardiol., December 9, 2008; 52(24): 1981 - 1989. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pelliccia, D. P. Zipes, and B. J. Maron Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations Revisited: A Comparison of U.S. and European Criteria for Eligibility and Disqualification of Competitive Athletes With Cardiovascular Abnormalities J. Am. Coll. Cardiol., December 9, 2008; 52(24): 1990 - 1996. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Papadakis, G. Whyte, and S. Sharma Preparticipation screening for cardiovascular abnormalities in young competitive athletes BMJ, September 29, 2008; 337(sep29_1): a1596 - a1596. [Full Text] |
||||
![]() |
F. Sofi, A. Capalbo, N. Pucci, J. Giuliattini, F. Condino, F. Alessandri, R. Abbate, G. F. Gensini, and S. Califano Cardiovascular evaluation, including resting and exercise electrocardiography, before participation in competitive sports: cross sectional study BMJ, July 3, 2008; 337(jul03_2): a346 - a346. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. L. Vetter, J. Elia, C. Erickson, S. Berger, N. Blum, K. Uzark, and C. L. Webb Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing Circulation, May 6, 2008; 117(18): 2407 - 2423. [Full Text] [PDF] |
||||
![]() |
I. Ostman-Smith, G. Wettrell, B. Keeton, D. Holmgren, U. Ergander, S. Gould, C. Bowker, and M. Verdicchio Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy Eur. Heart J., May 1, 2008; 29(9): 1160 - 1167. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Basavarajaiah, M. Wilson, G. Whyte, A. Shah, W. McKenna, and S. Sharma Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J. Am. Coll. Cardiol., March 11, 2008; 51(10): 1033 - 1039. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pelliccia, F. M. Di Paolo, F. M. Quattrini, C. Basso, F. Culasso, G. Popoli, R. De Luca, A. Spataro, A. Biffi, G. Thiene, et al. Outcomes in Athletes with Marked ECG Repolarization Abnormalities N. Engl. J. Med., January 10, 2008; 358(2): 152 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Myerburg and V. L. Vetter Electrocardiograms Should Be Included in Preparticipation Screening of Athletes Circulation, November 27, 2007; 116(22): 2616 - 2626. [Full Text] [PDF] |
||||
![]() |
A. Pelliccia The preparticipation cardiovascular screening of competitive athletes: is it time to change the customary clinical practice? Eur. Heart J., November 2, 2007; 28(22): 2703 - 2705. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Q Osborn, W. C Taylor, K. Oken, M. Luzano, M. Heckman, and G. Fletcher Echocardiographic characterisation of left ventricular geometry of professional male tennis players Br. J. Sports Med., November 1, 2007; 41(11): 789 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kasikcioglu Gray zone problem in athletes Eur. Heart J., October 1, 2007; 28(19): 2415 - 2416. [Full Text] [PDF] |
||||
![]() |
A. Pelliccia, F. Culasso, F. M. Di Paolo, D. Accettura, R. Cantore, W. Castagna, A. Ciacciarelli, G. Costini, B. Cuffari, E. Drago, et al. Prevalence of abnormal electrocardiograms in a large, unselected population undergoing pre-participation cardiovascular screening Eur. Heart J., August 2, 2007; 28(16): 2006 - 2010. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nistri, I. Olivotto, F. Cecchi, C. Basso, and G. Thiene ECG-based screening: not only for athletes Eur. Heart J., May 1, 2007; 28(9): 1170 - 1170. [Full Text] [PDF] |
||||
![]() |
D. Corrado, A. Pelliccia, H. H. Bjornstad, G. Thiene, and On behalf of the Study Group on Sports Cardiology Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol: reply Eur. Heart J., December 1, 2006; 27(23): 2905 - 2906. [Full Text] [PDF] |
||||
![]() |
D. Corrado, C. Basso, A. Pavei, P. Michieli, M. Schiavon, and G. Thiene Trends in Sudden Cardiovascular Death in Young Competitive Athletes After Implementation of a Preparticipation Screening Program JAMA, October 4, 2006; 296(13): 1593 - 1601. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Panhuyzen-Goedkoop and F. W.A. Verheugt Sudden cardiac death due to hypertrophic cardiomyopathy can be reduced by pre-participation cardiovascular screening in young athletes Eur. Heart J., September 2, 2006; 27(18): 2152 - 2153. [Full Text] [PDF] |
||||






